HomeAboutScientific TeamCode of Good PracticeResearchCOVID-19 TestingCardiac HealthClinical Trial Design & MethodologyHepatologyEthnic and Sex Differences Physiology & Drug ResponsesPublicationsNewsCareersSupportContact

What’s a Rich Text element? (H1)

The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.

What’s a Rich Text element? (H2)

The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.

Static and dynamic content editing (H3)

A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!

How to customize formatting for each rich text (H4)

Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.

How to customize formatting for each rich text (H5)

Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.

How to customize formatting for each rich text (H6)

Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.

  • Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.
  • Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.
  • Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.

HFA 2025

4th July 2025

Richmond Research Institute is proud to take part in Heart Failure 2025, the annual congress of the Heart Failure Association of the ESC, to be held this year in Serbia. This flagship event provides a vital forum for advancing clinical practice, scientific innovation, and global collaboration in the field of heart failure and related cardiovascular diseases.

Gathering leading experts from around the world, the congress will showcase cutting-edge developments in cardiology, digital health, and novel strategies for managing heart failure.

Attending on behalf of Richmond Research Institute:

  • Dr Jörg Täubel, Chief Executive Officer
  • James Rickard, Chief Scientific Officer

James Rickard will present two research posters and will be available throughout the event to discuss Richmond Research Institute’s role in cardiovascular drug development. His presentations will cover:

  1. The use of Symmetric Projection Attractor Reconstruction (SPAR) to detect ECG changes corresponding to cardiac deterioration in transthyretin amyloid cardiomyopathy (ATTR-CM).
  2. Disparities in Clinical Trial Access for Black Patients with ATTR-CM. Investigating racial disparities in access to clinical trials for ATTR-CM, particularly among Black African and Black Caribbean patients.

If you’ll be attending HFA 2025 and are looking for an experienced partner in cardiovascular research, we welcome the opportunity to connect.

For meeting requests or collaboration enquiries:
📧 info@richmondresearchinstitute.com

Learn more about the event: Heart Failure 2025

Related News

First patient enrolled in telehealth study, the Pathway Study

The Pathway study is based on pioneering work during the pandemic between clinicians at Richmond Pharmacology and...

Characterisation of the Cardiovascular Effects of a Meal: QTcF Assessment and Further Insights into the Physiological Effects

Authored by Georg Ferber, PhD, Dilshat Djumanov, PhD, Ulrike Lorch, MD, FFPM, Edward Jackson, BSc, MSc, PhD, MBChB, Joao Almeida Melo, James Rickard, MPharm, and Jorg Taubel, MD, FFPM, FESC.

Dr Dominic Pimenta wins the 'Young Investigators Award for Primary Care and Risk Factor Management'

RRI Lead Specialty Research Physician wins award for Cardiovascular risk factor analysis of data associated with UK grocery brand Tescos

RRI study finds antimalaria drug has no negative impact on cardiac safety in healthy volunteers

We studied the cardiac safety of P218 using advanced QTc assessments and found doses of up to 1000mg do not prolong the QTc suggesting a low risk of drug induced arrhythmia.

Phase I study confirms cardiac safety of potential alopecia treatment

Here we present the results of our recent work on the cardiac safety of cortexolone 17α-propionate (cortexolone).

Effectiveness of 12-lead ECG versus Holter monitor confirmed in important trial methodology

12-lead resting ECGs are considered essential in clinical trials, but their limitations have led to increasing use of 12-lead Holter monitor devices.

Why patient safety is paramount in patient trials

Dr. Taubel explains to the New Scientist why patient safety is pivotal in phase I trials

Cardiac safety of nolasiban confirmed in Phase I clinical trial

Here we report our recent work on the cardiac safety of nolasiban.

Why more caution is needed in administering QT prolonging drugs to type 1 diabetic patients.

Findings from our recent study show how cardiac ion channel blocking agents could increase the risk of sudden cardiac death in patients with type 1 diabetes, particularly in women.

Back to News